Mineralys Therapeutics (NASDAQ:MLYS) presented clinical data for lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection. The biotech, valued at $2.6 billion, has surged 102% over the past year but remains unprofitable.
A post hoc analysis of the Phase 3 Launch-HTN trial evaluated 50 mg lorundrostat in 800 participants with uncontrolled or resistant hypertension. Of these, 192 had chronic kidney disease.
At 12 weeks, placebo-adjusted systolic blood pressure reductions were 9.6 mmHg in kidney disease patients and 12.2 mmHg in those without. Target blood pressure (<130 mmHg) was achieved by 44% (kidney) and 48% (non-kidney) on lorundrostat vs 18% and 22% on placebo.
In 84 kidney disease patients with albuminuria, lorundrostat reduced the urinary albumin-to-creatinine ratio by 52.2% vs placebo. Hyperkalemia rates were low: 2.4% in kidney patients and 0% in non-kidney patients.
